Abstract: The present invention relates to compounds comprising at least ten contiguous amino acids of the HR2 domain of a Type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the C-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus.
Type:
Application
Filed:
September 10, 2013
Publication date:
April 3, 2014
Applicant:
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.r.l.
Inventors:
Antonello PESSI, Elisabetta Bianchi, Paolo Ingallinella
Abstract: The present invention relates to compounds comprising at least ten contigous amino acids of the HR2 domain of a Type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the C-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus.
Type:
Grant
Filed:
October 20, 2008
Date of Patent:
January 14, 2014
Assignee:
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.r.l.
Inventors:
Antonello Pessi, Elisabetta Bianchi, Paolo Ingallinella
Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use treating or preventing HCV infections.
Type:
Grant
Filed:
October 19, 2007
Date of Patent:
February 19, 2013
Assignees:
Merck Sharp & Dohme Corp., Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L.
Inventors:
Nigel J. Liverton, Vincenzo Summa, Joseph P. Vacca, Maria Emilia Di Francesco, Marco Pompei
Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.
Type:
Grant
Filed:
March 13, 2009
Date of Patent:
January 29, 2013
Assignee:
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L.
Inventors:
Raffaele Ingenito, Philip Jones, Laura Llauger Bufi, Jesus Maria Ontoria Ontoria, Rita Scarpelli
Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.
Type:
Grant
Filed:
August 21, 2008
Date of Patent:
January 15, 2013
Assignee:
Istituto di Ricerche di Biologia Molecolare P. Angeletti, S.R.L.
Inventors:
Philip Jones, Olaf Kinzel, Uwe Koch, Jesus Maria Ontoria Ontoria, Giovanna Pescatore, Rita Scarpelli, Caterina Torrisi